Genomic Valley Biotech Ratios

Genomic Valley Biotech Ltd Ratios

The Genomic Valley Biotech Ltd Ratios page provides a complete fundamental analysis of Genomic Valley Biotech Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Genomic Valley Biotech Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Genomic Valley Biotech Ltd (NSE: , BSE: 539206) is currently trading at ₹28.56, with a market capitalization of ₹0. As a major player in the Health technology sector and Biotechnology industry, Genomic Valley Biotech Ltd remains a key stock for fundamental analysis using Genomic Valley Biotech Ltd Ratios.

Genomic Valley Biotech Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Genomic Valley Biotech Ltd P/E ratio currently stands at 0, making it one of the most tracked metrics in Genomic Valley Biotech Ltd Ratios.

Historically, the Genomic Valley Biotech Ltd P/E ratio has shown strong fluctuations:

The decline in Genomic Valley Biotech Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Genomic Valley Biotech Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 0.

Historical P/B trend:

Genomic Valley Biotech Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Genomic Valley Biotech Ltd P/S ratio currently stands at 0, an important part of Genomic Valley Biotech Ltd Ratios for revenue valuation.

Historical P/S ratio:

A stable or declining Genomic Valley Biotech Ltd P/S ratio indicates cautious market sentiment.

Genomic Valley Biotech Ltd Price to Cash Flow Ratio (P/CF)

The Genomic Valley Biotech Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.

Historical Genomic Valley Biotech Ltd Price to Cash Flow Ratio:

The declining Genomic Valley Biotech Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Genomic Valley Biotech Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Genomic Valley Biotech Ltd EV currently stands at ₹0, representing the total company valuation including debt.

Historical EV trend:

Genomic Valley Biotech Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Genomic Valley Biotech Ltd EV/EBITDA ratio is currently 0, a key metric in Genomic Valley Biotech Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

Stable Genomic Valley Biotech Ltd EV/EBITDA indicates balanced valuation.

Genomic Valley Biotech Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Genomic Valley Biotech Ltd D/E ratio is currently 0, reflecting leverage and financial stability.

Historical D/E:

Genomic Valley Biotech Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Genomic Valley Biotech Ltd ROE currently stands at 0%, showing profitability and capital efficiency.

Historical ROE:

Declining ROE indicates pressure on profitability.

Genomic Valley Biotech Ltd Ratios Analysis Summary

The Genomic Valley Biotech Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Genomic Valley Biotech Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Genomic Valley Biotech Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.